Characteristics of all patients with clinically relevant inhibitors
| . | All inhibitors . | Range . | High-titer* inhibitors . | Range . | Low-titer inhibitors . | Range . |
|---|---|---|---|---|---|---|
| No. patients (%) | 87 (24) | NA | 69 (79) | NA | 18 (21) | NA |
| Median no. exposure days at inhibitor development (IQR) | 14 (8-21) | 2-50 | 14 (8-22) | 2-50 | 14 (6-20) | 2-43 |
| Median age at inhibitor development, mo (IQR) | 15 (10-22) | 0.3-79 | 15 (10-22) | 0.3-79 | 17 (10-26) | 10-47 |
| Median duration between first exposure day and inhibitor development, mo (IQR) | 5 (2-12) | 0.2-60 | 5 (2-11) | 0.2-60 | 8 (4-18) | 1-47 |
| . | All inhibitors . | Range . | High-titer* inhibitors . | Range . | Low-titer inhibitors . | Range . |
|---|---|---|---|---|---|---|
| No. patients (%) | 87 (24) | NA | 69 (79) | NA | 18 (21) | NA |
| Median no. exposure days at inhibitor development (IQR) | 14 (8-21) | 2-50 | 14 (8-22) | 2-50 | 14 (6-20) | 2-43 |
| Median age at inhibitor development, mo (IQR) | 15 (10-22) | 0.3-79 | 15 (10-22) | 0.3-79 | 17 (10-26) | 10-47 |
| Median duration between first exposure day and inhibitor development, mo (IQR) | 5 (2-12) | 0.2-60 | 5 (2-11) | 0.2-60 | 8 (4-18) | 1-47 |
NA indicates not applicable
*High-titer inhibitor was defined as clinically relevant inhibitor with a peak titer of at least 5 BU/mL.